1
|
Goyache I, Yavorov-Dayliev D, Milagro FI, Aranaz P. Caenorhabditis elegans as a Screening Model for Probiotics with Properties against Metabolic Syndrome. Int J Mol Sci 2024; 25:1321. [PMID: 38279322 PMCID: PMC10816037 DOI: 10.3390/ijms25021321] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/22/2023] [Revised: 01/17/2024] [Accepted: 01/18/2024] [Indexed: 01/28/2024] Open
Abstract
There is a growing need to develop new approaches to prevent and treat diseases related to metabolic syndromes, including obesity or type 2 diabetes, that focus on the different factors involved in the pathogenesis of these diseases. Due to the role of gut microbiota in the regulation of glucose and insulin homeostasis, probiotics with beneficial properties have emerged as an alternative therapeutic tool to ameliorate metabolic diseases-related disturbances, including fat excess or inflammation. In the last few years, different strains of bacteria, mainly lactic acid bacteria (LAB) and species from the genus Bifidobacterium, have emerged as potential probiotics due to their anti-obesogenic and/or anti-diabetic properties. However, in vivo studies are needed to demonstrate the mechanisms involved in these probiotic features. In this context, Caenorhabditis elegans has emerged as a very powerful simple in vivo model to study the physiological and molecular effects of probiotics with potential applications regarding the different pathologies of metabolic syndrome. This review aims to summarize the main studies describing anti-obesogenic, anti-diabetic, or anti-inflammatory properties of probiotics using C. elegans as an in vivo research model, as well as providing a description of the molecular mechanisms involved in these activities.
Collapse
Affiliation(s)
- Ignacio Goyache
- Faculty of Pharmacy and Nutrition, Department of Nutrition, Food Sciences and Physiology, University of Navarra, 31008 Pamplona, Spain (P.A.)
- Center for Nutrition Research, University of Navarra, 31008 Pamplona, Spain
| | - Deyan Yavorov-Dayliev
- Faculty of Pharmacy and Nutrition, Department of Nutrition, Food Sciences and Physiology, University of Navarra, 31008 Pamplona, Spain (P.A.)
- Center for Nutrition Research, University of Navarra, 31008 Pamplona, Spain
- Genbioma Aplicaciones SL, Polígono Industrial Noain-Esquiroz, Calle S, Nave 4, 31191 Esquíroz, Spain
| | - Fermín I. Milagro
- Faculty of Pharmacy and Nutrition, Department of Nutrition, Food Sciences and Physiology, University of Navarra, 31008 Pamplona, Spain (P.A.)
- Center for Nutrition Research, University of Navarra, 31008 Pamplona, Spain
- Navarra Institute for Health Research (IdiSNA), 31008 Pamplona, Spain
- Spanish Biomedical Research Centre in Physiopathology of Obesity and Nutrition (CIBERObn), 28029 Madrid, Spain
| | - Paula Aranaz
- Faculty of Pharmacy and Nutrition, Department of Nutrition, Food Sciences and Physiology, University of Navarra, 31008 Pamplona, Spain (P.A.)
- Center for Nutrition Research, University of Navarra, 31008 Pamplona, Spain
- Navarra Institute for Health Research (IdiSNA), 31008 Pamplona, Spain
| |
Collapse
|